Articles + guides.
Editorial deep-dives on telehealth programs, treatment options, and how to choose wisely. Each piece cites primary sources and is reviewed by licensed clinicians where noted.
CagriSema: the amylin + GLP-1 combo and what REDEFINE actually showed (2026)
CagriSema pairs semaglutide with cagrilintide, an amylin analog — a different mechanism from tirzepatide or retatrutide. Its phase 3 REDEFINE 1 trial showed about 20% average weight loss at 68 weeks. Here's the evidence, how it differs, and its status.
·4 min read·Editorial-reviewed
- Weight Loss
GLP-1 drugs and gallstones: the real risk, why it happens, and what to watch (2026)
GLP-1 medications raise the risk of gallbladder and biliary disease — a 76-trial meta-analysis found the risk more than doubled in weight-loss trials. Here's why it happens, the actual numbers, the warning signs, and how to lower your risk.
·6 min·Reviewed
- Weight Loss
Retatrutide: the triple-agonist obesity drug and its record 24% weight loss (2026)
Retatrutide is an investigational triple-hormone-receptor agonist that produced the largest average weight loss of any obesity drug published to date — about 24% at 48 weeks in its phase 2 trial. Here's what the evidence shows, how it differs from Wegovy and Zepbound, and its actual status.
·6 min·Reviewed
- Weight Loss
Orforglipron: the once-daily GLP-1 pill and what its phase 3 trial showed (2026)
Orforglipron is an investigational oral GLP-1 drug — a true once-daily pill with no food or water timing rules. Its phase 3 obesity trial showed about 11% average weight loss at 72 weeks. Here's how it compares to injections and to Rybelsus, and where it stands.
·5 min·Reviewed
- Weight Loss
Peptides for weight loss: what actually works, what's unproven, what's illegal
The only weight-loss peptides with FDA approval and large human trials are the GLP-1 drugs — semaglutide (~15% mean loss in STEP-1) and tirzepatide (~21% in SURMOUNT-1). Most products marketed online as 'weight-loss peptides' (BPC-157, ipamorelin, 'research-grade' retatrutide) have no human efficacy trials, no FDA oversight, and no sterility assurance.
·2 min·Reviewed
- ED Treatment
Rhino pills: why the FDA keeps finding hidden sildenafil in 'natural' ED supplements
Gas-station ED pills marketed as 'natural' (Rhino, and hundreds of similar brands) are repeatedly found by FDA testing to contain undeclared sildenafil or tadalafil — real prescription drugs at unknown doses. That makes them dangerous for anyone on nitrates, and pointless for everyone else: you're taking Viagra's active ingredient without the dosing, screening, or purity control.
·2 min·Reviewed
- Hair Loss
Minoxidil timeline: when it starts working, why shedding happens first
Minoxidil results follow a predictable arc: initial shedding in weeks 2-8 (a sign follicles are cycling, not failing), first visible regrowth around months 2-4, and full assessable effect at 6-12 months. Quitting during the shed — the most common mistake — resets the clock to zero.
·2 min·Reviewed
- Testosterone
Enclomiphene for testosterone: the evidence, and what telehealth ads don't say
Enclomiphene raises testosterone by stimulating your own production — and unlike testosterone replacement, it preserves sperm counts. The part the ads skip: it is not FDA-approved (the Androxal application was not approved in 2015), so every enclomiphene prescription today is off-label compounded medication.
·2 min·Reviewed
- Weight Loss
Stopping a GLP-1 before surgery: what the anesthesia guidance actually says (2026)
GLP-1 medications slow how fast your stomach empties, which raises the aspiration risk under anesthesia even after normal fasting. Here is what the ASA guidance and the 2024 update say about when to hold your dose — and what changed.
·5 min·Reviewed
- Weight Loss
Zepbound for sleep apnea: what the FDA approval and SURMOUNT-OSA actually showed (2026)
In December 2024 tirzepatide (Zepbound) became the first drug FDA-approved for obstructive sleep apnea. Here is what the SURMOUNT-OSA trials measured, how much it reduced apnea events, and who the approval is — and isn't — for.
·4 min·Reviewed
- Weight Loss
Does Ozempic affect birth control? What the GLP-1 labels actually say (2026)
The oral-contraceptive warning belongs to tirzepatide (Mounjaro, Zepbound), not semaglutide. Here is exactly what each FDA label says, why the difference exists, and what to do about backup contraception — in plain terms.
·4 min·Reviewed
- Weight Loss
Wegovy for heart disease: the SELECT trial and the cardiovascular indication (2026)
In 2024 Wegovy became the first weight-loss drug FDA-approved to cut cardiovascular risk. The basis was SELECT, a 17,604-patient trial that reduced heart attacks, strokes, and CV death by 20%. Here is what it showed and why it changed coverage.
·5 min·Reviewed
- Weight Loss
Modern Fertility AMH testing: what 95th vs 5th percentile means (2026)
An AMH result at the 5th percentile doesn't mean infertility, and a result at the 95th percentile doesn't mean abundant fertility. Here's what the test actually measures and what high or low values predict.
·5 min·Reviewed
- Weight Loss
Ozempic for PCOS: off-label evidence 2026 review
Semaglutide is being prescribed off-label for PCOS more often each year. Here's what the published trials actually show on weight, ovulation, insulin resistance, and androgen levels — and what they don't.
·4 min·Reviewed
- Weight Loss
Wegovy prior authorization: the step-by-step approval playbook (2026)
Wegovy denials usually come from incomplete documentation, not clinical ineligibility. Here's the exact step-by-step process that gets approval on the first submission, plus what to do when denied.
·5 min·Reviewed
- Weight Loss
GLP-1 hair loss timeline: when it starts, peaks, and recovers (2026)
Hair shedding on Wegovy, Ozempic, or Zepbound follows a predictable pattern tied to rapid weight loss, not the drug itself. Here's the week-by-week timeline, why it happens, and what actually shortens recovery.
·4 min·Reviewed
- Weight Loss
Wegovy vs Ozempic in 2026: same drug, different prescribing rules
Wegovy and Ozempic are both semaglutide. Wegovy is FDA-approved for weight management; Ozempic for type 2 diabetes. Same active ingredient — but different dose, different insurance pathway, different cost, and different clinical conversation. Here's the full comparison.
·4 min·Reviewed
- Weight Loss
Mounjaro vs Zepbound (2026): tirzepatide split by indication
Mounjaro and Zepbound are both tirzepatide — Eli Lilly's dual GLP-1/GIP agonist. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. Here's the regulatory split, dose ladder, insurance reality, and how to switch.
·3 min·Reviewed
- Weight Loss
Wegovy cost without insurance in 2026: cheapest legitimate paths
Wegovy's pharmacy list price is ~$1,349 per month. For uninsured patients, the cheapest legitimate paths in 2026 are NovoCare self-pay at $499/month, transitioning to oral orforglipron at $149/month when prescriber agrees, or compounded semaglutide (a narrowing legal grey zone). Here are the actual options and what's changing.
·4 min·Reviewed
- Weight Loss
Wegovy weight loss timeline: week-by-week expectations (2026)
Wegovy doesn't drop the scale immediately. Most patients lose 1-2 pounds in weeks 1-4, hit a 5% loss around month 4, reach 10% by month 8, and approach 15% by week 68. Here's what to actually expect, what's normal during titration, and when to call your prescriber if results lag.
·4 min·Reviewed
- Weight Loss
Ozempic injection sites and technique: complete how-to (2026)
Ozempic is injected once weekly under the skin (subcutaneous) of your abdomen, thigh, or upper arm. Site rotation matters — repeated injection in one spot causes lipohypertrophy that reduces drug absorption. Here's the full technique, site rotation schedule, what to avoid, and how to troubleshoot common problems.
·4 min·Reviewed
- Weight Loss
Foods to avoid on GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) in 2026
GLP-1 medications slow gastric emptying — foods that already sit heavy in the stomach (fried, high-fat, fibrous) become much worse. Sulfur-rich foods (eggs, alliums, cruciferous) trigger sulfur burps. Alcohol, carbonated drinks, and spicy foods worsen nausea. Here's the complete avoidance + substitution guide.
·4 min·Reviewed
- Weight Loss
GLP-1 medications and alcohol in 2026: what to know
GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) are not FDA-contraindicated with alcohol, but most patients find alcohol tolerance significantly reduced. Slowed gastric emptying means the same drink hits harder and later. Many patients lose interest in alcohol entirely. Here's the science, the practical limits, and the situations to avoid.
·4 min·Reviewed
- Weight Loss
Wegovy vs Ozempic side effects in 2026: complete comparison
Wegovy and Ozempic are both semaglutide so the side-effect profile is nearly identical: nausea, constipation, diarrhea, vomiting, fatigue. Differences exist primarily because Wegovy goes to a higher max dose (2.4mg vs 2.0mg), which means slightly more frequent and severe GI side effects. Here's the head-to-head data, what to expect, and how to manage.
·4 min·Reviewed
- Weight Loss
Does BCBS cover Wegovy in 2026? Blue Cross coverage by plan type
Blue Cross Blue Shield coverage of Wegovy varies dramatically by state, employer plan, and member type. Federal BCBS (FEP) covers Wegovy. Many commercial BCBS plans require prior authorization with BMI ≥30 + comorbidity. Some plans exclude obesity medications entirely. Here's how to check your specific BCBS plan + what to do if denied.
·4 min·Reviewed
- Weight Loss
Oral vs injection GLP-1 in 2026: Rybelsus, orforglipron, and the injectables
Three oral GLP-1 options exist in 2026: Rybelsus (oral semaglutide for diabetes), oral semaglutide 25mg (oral Wegovy for weight loss, filed with the FDA under the OASIS program), and orforglipron (Eli Lilly's oral GLP-1). Each has trade-offs vs injectable Wegovy/Ozempic. Here's the head-to-head, efficacy data, and practical guidance.
·4 min·Reviewed
- Weight Loss
Compounded semaglutide near me in 2026: where it's actually still available
Compounded semaglutide availability has dramatically narrowed in 2026. FDA proposed permanently ending 503B mass compounding April 30, 2026. Hims exited February 2026 amid Novo Nordisk lawsuit. State boards of pharmacy enforce at different paces. Here's the actual map of where compounded semaglutide is still findable, plus legitimate alternatives.
·4 min·Reviewed
- Weight Loss
Best GLP-1 telehealth program in 2026: comparison of legitimate options
After Hims exited compounded GLP-1 in February 2026, the telehealth landscape consolidated significantly. The best programs in 2026 are Ro (clinical concierge), Sequence/WeightWatchers (lifestyle integration), Calibrate (high-touch coaching), and manufacturer direct paths (NovoCare and LillyDirect). Here's how to choose based on insurance status, dose preference, and clinical needs.
·3 min·Reviewed
- Weight Loss
Does Aetna cover Wegovy in 2026? Prior authorization + appeals guide
Aetna's Wegovy coverage depends on your specific plan. Most commercial Aetna plans cover Wegovy with prior authorization requiring BMI ≥30 (or ≥27 + comorbidity) plus documentation of structured weight-loss attempts. Medicare Advantage generally cannot cover for weight loss only. Here's how to check, the typical PA process, and appeal strategies.
·3 min·Reviewed
- Weight Loss
Ozempic before and after in 2026: realistic results month-by-month
Ozempic results vary widely — STEP-1 trial showed mean 14.9% weight loss for semaglutide at the higher Wegovy dose, but on Ozempic's 2.0mg max dose for T2D, expect 6-10% over 6-9 months. Visual changes follow scale weight closely. Here's what realistic before/after looks like month-by-month and why social media expectations can be misleading.
·4 min·Reviewed
- Weight Loss
Wegovy maintenance dose strategy in 2026: microdosing vs full dose
Wegovy's FDA-approved maintenance dose is 2.4mg weekly, but not every patient needs the maximum. Some patients maintain weight loss at 1.7mg, 1.0mg, or even 0.5mg with substantially fewer side effects. Here's the clinical reality of maintenance dose options, when to use each, and why 'microdose maintenance' is increasingly common.
·4 min·Reviewed
- Weight Loss
Does Cigna cover Wegovy in 2026? Prior auth, step therapy, and appeal paths
Cigna's commercial plans cover Wegovy on most formularies but enforce one of the strictest step-therapy protocols in the industry. Here's how the criteria look, what gets denied, and the appeal playbook that wins.
·4 min·Reviewed
- Weight Loss
Telehealth privacy: how PHI flows in 503A compounding (2026)
When you sign up for a telehealth GLP-1 subscription, your PHI passes through 3-5 distinct entities — provider group, telehealth platform, pharmacy, sometimes a marketing platform. Here's the realistic map.
·5 min·Reviewed
- Weight Loss
Wegovy stopped working: why it happens and what to do next
After 6-12 months on Wegovy, some patients see weight loss stall or regain. The cause is rarely 'the drug stopped working' — it's biology, dose ceiling, or adherence. Here's how to diagnose what actually happened and the evidence-based moves.
·2 min·Reviewed
- Weight Loss
GLP-1 plateau after 6 months: 4 evidence-based moves that actually help
Plateau is the most common 'is this working?' moment on a GLP-1. The body defends weight loss aggressively. Here are the four moves with the best evidence for breaking through, and the three popular strategies the data doesn't support.
·2 min·Reviewed
- Weight Loss
Tirzepatide non-response: switch, escalate, or stop?
5-8% of patients see <5% weight loss on max-dose tirzepatide after 12 months. This is true treatment-resistant obesity, not a willpower issue. Here's the decision framework: what to try next, when to consider surgery, and what 'success' realistically looks like.
·2 min·Reviewed
- Weight Loss
Coming off Wegovy without losing your progress: the 2026 evidence
If you've decided to stop Wegovy — for cost, side effects, pregnancy planning, or other reasons — the question becomes: how do I avoid regaining everything? Here's what the trials show about regain, and the specific structured strategies that minimize it.
·2 min·Reviewed
- Weight Loss
Why patients stop Zepbound — and what they wish they'd done differently
An editorial synthesis of why people discontinue tirzepatide and the regain that often follows, drawn from published discontinuation research (SURMOUNT-4) and documented clinical patterns — not a single patient's account. The lessons that hold across cases, and the structural advice that minimizes regret.
·2 min·Reviewed
- Weight Loss
GLP-1 medications and chronic kidney disease (CKD): dosing, monitoring, what to know
GLP-1 agonists have emerged as one of the most important new tools for CKD progression a renal-cardiovascular outcomes. Here's the 2026 evidence on which patients benefit, dose adjustments at each eGFR stage, monitoring guidance, and red-flag scenarios.
·2 min·Reviewed
- Weight Loss
GLP-1 medications and thyroid history: MTC, MEN2, nodules, what's actually a contraindication
Every GLP-1 carries a boxed warning about medullary thyroid carcinoma. But what does that mean for the millions of patients with thyroid nodules, family history, or Hashimoto's? Here's what the warning actually means, what's a real contraindication, and what just requires monitoring.
·3 min·Reviewed
- Weight Loss
GLP-1s with IBS, Crohn's, ulcerative colitis: what to expect and how to manage
GLP-1 medications slow gastric emptying — a feature for weight loss, potential problem for patients with existing IBS, IBD, or motility disorders. Here's what the evidence shows about each condition, when to use, when to avoid, and the modifications that help.
·2 min·Reviewed
- ED Treatment
PDE5 inhibitors and nitrates: the one combination that's genuinely dangerous
Most ED medication 'interactions' aren't dangerous. One is — nitrates. Understanding why, what counts as a nitrate, how long you have to wait, and what to do if you've taken both is genuinely life-saving information.
·2 min·Reviewed
- Hair Loss
Finasteride and depression history: post-finasteride syndrome, what we know, what to ask
Finasteride has a documented but uncommon association with persistent sexual, neurological, and mood effects after discontinuation. The science is unsettled, the medical community is divided, and patients with depression history have legitimate questions. Here's the honest 2026 picture.
·2 min·Reviewed
- Weight Loss
Ozempic face: what causes it, who gets it, and what helps in 2026
The hollow-cheeks look people call 'Ozempic face' isn't a drug side effect — it's a consequence of rapid fat loss combined with skin elasticity that hasn't caught up. Here's what the evidence shows, who's most at risk, and the dermatologically-grounded options that actually help.
·3 min·Reviewed
- Weight Loss
GLP-1 hair loss (Ozempic, Wegovy, Zepbound): why it happens and what helps
Hair shedding on GLP-1 medications is real, common, and usually temporary. The driver is rapid weight loss triggering telogen effluvium, not the drug itself. Here's how to tell which type of hair loss you have, what helps, and when to escalate to a dermatologist.
·3 min·Reviewed
- Weight Loss
Sulfur burps on Ozempic, Wegovy, Zepbound: why they happen and what helps
Rotten-egg burps are one of the most-searched GLP-1 side effects and rarely covered honestly. They're caused by slowed gastric emptying letting sulfur-producing bacteria work longer on protein-rich food. Here's the mechanism, food triggers to avoid, and what actually helps.
·3 min·Reviewed
- Weight Loss
Semaglutide microdosing in 2026: what the evidence actually shows
Microdosing semaglutide — using doses well below the FDA-approved 0.25-2.4mg range — has surged on social media as a 'gentler' approach. We look at what the trials actually tested, what compounding pharmacies are dispensing, and where microdosing genuinely makes sense vs where it's marketing.
·3 min·Reviewed
- Weight Loss
Bariatric surgery vs GLP-1 medications in 2026: which is right for you
The conversation that started with 'surgery vs. nothing' became 'surgery vs. semaglutide' became 'surgery vs. tirzepatide vs. retatrutide-in-trials'. Here's the honest 2026 comparison: efficacy, durability, cost, and the patient profiles each option fits.
·3 min·Reviewed
- Weight Loss
GLP-1 and pregnancy: washout period, conception planning, and what to do if you find out you're pregnant
FDA labels for Wegovy, Zepbound, Ozempic, and Mounjaro all recommend discontinuation before pregnancy. Here's the actual washout timeline, what to do for planned conception, and what to do if you discover an unplanned pregnancy on a GLP-1.
·3 min·Reviewed
- Weight Loss
GLP-1 pen injection technique (Wegovy, Ozempic, Zepbound, Mounjaro): step-by-step
Self-injection is the most-questioned part of GLP-1 treatment. Done correctly, it takes 10 seconds and is painless for most patients. Here's the step-by-step technique, rotation schedule, what to do if a dose goes wrong, and the safety habits worth establishing from week 1.
·4 min·Reviewed
- Weight Loss
Compounded GLP-1 in 2026: the complete legal map (post-503B rule)
What 'compounded' actually means, where the law stands after the April 2026 FDA rule, what's still legitimate, what isn't, and how to read a program's compliance posture in 10 minutes.
·6 min·Reviewed
- Weight Loss
Oral vs injectable GLP-1 in 2026: efficacy, side effects, and the orforglipron pivot
How the new oral GLP-1s (orforglipron, oral semaglutide 25 mg) stack up against the weekly injectables on efficacy, side effects, cost, and lifestyle fit — with the decision framework that actually helps you pick.
·5 min·Reviewed
- Weight Loss
GLP-1 exit strategy: the evidence on stopping, regain, and the off-ramp that actually works
Stopping a GLP-1 reliably leads to weight regain — the question is how much, how fast, and what behavior layer cushions the transition. Here's what the trial extension data actually shows and how to plan an exit that holds.
·6 min·Reviewed
- Hair Loss
Hair transplant vs finasteride: cost and outcome comparison (2026)
A hair transplant costs $4,000-15,000 upfront and treats existing loss. Finasteride costs $20-60/month and prevents future loss. Here's the realistic comparison most clinics don't give you.
·5 min·Reviewed
- Weight Loss
GLP-1 side effects: a week-by-week management playbook (2026)
Nausea, constipation, and the other GLP-1 side effects follow a predictable curve. Here's what to expect at each dose step and the evidence-based tactics that keep most people on treatment.
·8 min·Reviewed
- Weight Loss
The complete GLP-1 cost guide (2026): every price, every path
What Wegovy, Zepbound, Ozempic, Mounjaro, and the new oral GLP-1s actually cost in 2026 across insurance, manufacturer direct-pay, and telehealth, with the math for each access path.
·7 min·Reviewed
- Weight Loss
When to start tapering off a GLP-1: clinician decision framework (2026)
Most weight regained after GLP-1 discontinuation happens within 12 months. Here's the evidence-based framework clinicians use to decide when (and whether) to taper, and the protocols that minimize rebound.
·5 min·Reviewed
- Weight Loss
How to actually get a GLP-1 covered by insurance: the 2026 playbook
Coverage is winnable more often than people think. The step-by-step process: confirm your formulary, document the comorbidity, navigate prior authorization, and appeal a denial.
·2 min·Reviewed
- Weight Loss
Compounded GLP-1 availability in 2026: who's still shipping, who's stopped
On April 30, 2026 the FDA proposed permanently ending mass compounding of semaglutide and tirzepatide, issued 30 warning letters, and opened a comment period through June 29. Hims already exited. Here's who's still operating and what to do.
·2 min
- ED Treatment
ED medication telehealth: a real cost comparison in 2026
Generic sildenafil costs $40-90/month across telehealth brands for the same active ingredient. We mapped the actual delivered price after intake fees, shipping, and renewal terms.
·2 min
- Weight Loss
Telehealth prescribing rules: state-by-state changes in 2026
Eight states tightened controlled-substance telehealth in early 2026 after the federal DEA rule expired. Here's what changed and where you can still get care online.
·2 min
- Hair Loss
Finasteride vs dutasteride for hair loss: the honest 2026 comparison
Dutasteride blocks DHT more completely than finasteride. It's also off-label for hair, has weaker safety data, and costs more. When the trade-off makes sense.
·2 min
- Face Skincare
Tretinoin strength: how to pick (a how telehealth platforms differ)
Tretinoin comes in 0.025% to 0.1%. Higher isn't better. The right strength depends on your skin tolerance, condition, and how patient you are with irritation.
·2 min
- Weight Loss
How to afford Wegovy when insurance excludes weight-loss drugs (2026)
About 30% of US employer plans still exclude weight-loss drugs entirely. Here's the realistic 2026 menu of cash-pay paths, manufacturer programs, and tax-advantaged options when your plan won't cover Wegovy.
·5 min·Reviewed
- Weight Loss
Compounded vs branded GLP-1: legal status after FDA shortage removal (2026)
The FDA declared the semaglutide shortage resolved in early 2025 and proposed removing it from the 503B bulks list in 2026. Here's what that actually means for compounded GLP-1 access, legality, and clinical risk.
·4 min·Reviewed
- Weight Loss
GLP-1 muscle loss: evidence and countermeasures (2026)
About 25-40% of weight lost on GLP-1s comes from lean mass — similar to other rapid weight-loss methods. Here's what the trial data actually shows and the two interventions that meaningfully change the ratio.
·5 min·Reviewed